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Introduction: A signiﬁcant portion of adenoid cystic carcinoma 
(ACC) cases are characterized by a t(6;9)(q22-23;p23-24) transloca-
tion that originates a MYB–NFIB fusion oncogene. The MYB–NFIB 
fusion oncoprotein activates transcription of MYB-mediated path-
ways that impact cell cycle control, DNA repair, and apoptosis. This 
translocation seems highly speciﬁc for ACC. Moreover, therapies 
targeting MYB-activated pathways to treat ACC are being explored. 
Pulmonary ACC (PACC) has not been thoroughly studied for rear-
rangements of the MYB gene.
Methods: Mayo Clinic Rochester surgical pathology archives (1972–
2011) were searched for PACC. All cases were reviewed and classiﬁed 
according to the predominant histologic pattern (cribriform, solid, and 
tubular) by two surgical pathologists. Fluorescence in situ hybridiza-
tion (FISH) was employed using a break-apart strategy to detect MYB 
rearrangement (at 6q23.3). Medical records were studied.
Results: Forty cases of PACC were studied; tissue blocks were avail-
able for FISH analysis in 35 cases. Six cases failed to hybridize. In 
12 of 29 cases (41%), the MYB gene region was disrupted, whereas 
17 cases (59%) showed no evidence of rearrangement. FISH studies 
performed on other histologic subtypes of lung cancer (10 squamous 
cell carcinomas, 10 adenocarcinomas, and 10 small-cell carcinomas) 
failed to show MYB rearrangement. There was no signiﬁcant differ-
ence in MYB rearrangement status with respect to predominant histo-
logic pattern, clinical features, or clinical outcome.
Conclusions: A MYB rearrangement was identiﬁed in 41% of PACC 
and was 100% speciﬁc. FISH studies for MYB may be of diagnostic 
utility in PACC, particularly on small biopsy specimens. MYB rear-
rangement in PACC does not seem to be associated with clinical fea-
tures or prognosis.
Key Words: MYB rearrangement, Fluorescence in situ hybridization, 
Pulmonary adenoid cystic carcinoma, MYB–NFIB fusion, t(6;9).
(J Thorac Oncol. 2015;10: 1570–1575)
Primary pulmonary adenoid cystic carcinoma (PACC) is rare. Mucoepidermoid carcinoma and adenoid cystic car-
cinoma (ACC) are the most common primary salivary gland-
type carcinomas in the lung.1,2 PACC occur at a median age 
of 47 to 54 years with a relatively wide reported age range of 
21 to 76 years.1,2 They generally do not show a gender pre-
dominance.1 PACC can recur and metastasize. The 5-year 
disease-free survival has been reported as 46% with an overall 
survival of 53% to 89%.1,2
Primary PACC shows histomorphologic features identi-
cal to ACC at other anatomical sites. These tumors are charac-
teristically composed of two cellular components, ductal and 
myoepithelial cells. These cells usually surround a mucoid 
and/or hyalinized matrix. Tumor cells are typically arranged 
in a combination of three architectural growth patterns: 
tubular, cribriform, and solid. The distinction of PACC from 
small-cell or other non–small-cell carcinomas of the lung can 
be challenging, especially in the presence of a solid growth 
pattern and/or on small biopsy specimens. Although immuno-
histochemical staining for p63 and CD117 are often positive 
in ACC, they are not particularly useful in resolving the dif-
ferential diagnosis with small-cell and other non–small-cell 
carcinomas of the lung. In fact, p63 can be expressed in many 
other high-grade tumors of the lung, more speciﬁcally, not 
only squamous cell carcinoma but also adenocarcinoma and 
neuroendocrine carcinoma.3,4 CD117 is commonly expressed 
in small-cell lung carcinoma5–7 and also a subset of squamous 
cell carcinoma and adenocarcinoma.7 In addition, the expres-
sion of CD117 in ACC can be weak or focal. Nevertheless, the 
distinction between PACC and non–small-cell or small-cell 
lung carcinoma is crucial because of differences in clinical 
outcome and, to this end, treatment. Cases of PACC gener-
ally have a better outcome than other carcinomas in the lung.2 
Therefore, we sought to ﬁnd better markers that are speciﬁc 
for ACC and may facilitate making the diagnosis in the lung.
The translocation between chromosomes 6q and 9p 
(q22-23;p23-24) resulting in fusion of the MYB oncogene and 
the transcription factor gene NFIB has been identiﬁed in ACC 
of the head and neck and breast.8 The resulting MYB–NFIB 
fusion oncoprotein activates transcription of MYB-mediated 
pathways that impact cell cycle control, DNA repair, and 
apoptosis.8 The association of t(6;9) with clinical and prog-
nostic parameters is still controversial in ACC.9,10 Although 
initial studies identiﬁed the translocation in each ACC tested,8 
subsequent studies revealed the t(6;9) in 23% to 92% of head 
and neck and breast cases.9,11–13 Later, Brill et al.14 analyzed 
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10 cases of tracheobronchial ACC and found the t(6;9) in 5 
of them. This fusion has been shown to be highly speciﬁc to 
ACC among salivary gland-type tumors.9 Importantly, thera-
pies targeting MYB-activated pathways to treat ACCs are 
being explored.
Given the potential diagnostic and therapeutic utility 
of MYB rearrangement and the paucity of studies in PACC, 
we studied a large cohort of PACC. We sought to identify the 
frequency of MYB rearrangement in PACC and explore the 
association of this genetic event with clinical parameters and 
outcome. In addition, we tested for MYB rearrangement in 
lung carcinomas that morphologically mimic PACC.
PATIENTS AND METHODS
Patients and Specimens
Surgical pathology archives of Mayo Clinic Rochester 
(1972–2011) were searched for PACC. Clinical features of 
35 (of 40) cases were previously reported.2 Medical records 
were studied. In all cases, clinical and radiologic features 
of the tumor were suggestive of lung and/or tracheal origin. 
Cases with morphologic features of ACC were included as 
study cases. To evaluate for speciﬁcity of MYB rearrangement 
for ACC, adenocarcinomas, squamous cell carcinomas, and 
small-cell carcinomas of the lung were also selected.
The study was approved by the Mayo Clinic Rochester 
Institutional Review Board (#10-002733).
Histopathologic Criteria
Hematoxylin and eosin–stained slides from all selected 
study patients were reviewed independently by two surgical 
pathologists (A.C.R. and J.J.G.) who were blinded to clini-
cal information and immunohistochemical and cytogenetic 
results. PACC cases were classiﬁed according to the pre-
dominant histologic pattern (cribriform, solid, and tubular). 
Disagreements were resolved by consensus.
Immunohistochemical Staining
Formalin-ﬁxed parafﬁn-embedded (FFPE) tissue blocks 
were sectioned at 4 μm. Consecutive slides were stained 
with antibodies against p63 (clone BC4A4, Biocare Medical, 
Concord, CA) and CD117 (polyclonal, DAKO, Carpinteria, 
CA). p63 was considered positive if neoplastic cells showed 
nuclear staining. Cytoplasmic staining by CD117 in ductal 
tumor cells was considered positive.
Fluorescence In Situ Hybridization
MYB rearrangement was analyzed with break-apart 
fluorescence in situ hybridization (FISH). Human bacte-
rial artiﬁcial chromosomes flanking the MYB gene region 
were identiﬁed using the University of California Santa Cruz 
February 2009 Assembly hg19. The 5′MYB clones (CTD-
2533B20, RP11-366H19, and RP11-63K22) were labeled 
by nick translation with SpectrumOrange dUTP (Abbott 
Molecular/Vysis Products, Abbott Park, IL) and the 3′MYB 
clones (RP11-170P19, RP11-751F23, and RP11-259A7) 
were labeled with SpectrumGreen dUTP (Abbott Molecular/
Vysis Products). Labeled clones were combined to create a 
dual-color fusion break-apart (BAP) probe set. The BAP 
probe set was applied to individual slides, hybridized, and 
washed according to the Partially Automated Tissue Reduced 
Pepsin FISH protocol.
Slides were placed in a 90°C oven for 15 minutes. Slides 
were then deparafﬁnized with xylene (2 times, 15 min each) 
at room temperature (RT), dehydrated in 100% ethanol for 
5 minutes at RT, and placed in 10 mM citric acid (pH 6.0) and 
microwaved for 10 minutes. Following this, the slides were 
immersed in 2× standard saline citrate (SSC) for 5 minutes at 
37°C followed by digestion in 0.2% pepsin working solution 
(1.2 g pepsin/600 ml 0.9% NaCl, pH 2.5) at 37°C for 12 min-
utes. Immediately after digestion, the slides were dehydrated 
using an ethanol series (70%, 85%, 100%), 2 minutes each at 
RT. Working solution of BAP MYB (Mayo Clinic laboratory 
developed probe) was made by mixing 1 μl of concentrated 
5′MYB probe and 1 μl of concentrated 3′MYB probe with 8 
μl of LSI/WCP hybridization buffer (Abbott Laboratories). 
The working solution was applied to the target areas, cover-
slipped, codenatured with a ThermoBrite (Abbott Molecular) 
at 83°C for 5 minutes, and hybridized overnight in a 37°C 
humidiﬁed oven. Following hybridization, slides were soaked 
in RT 2×SSC/0.1% NP-40 to remove coverslips, placed in 
2×SSC/0.1% NP-40 at 74°C for 2 minutes, and then placed in 
RT 2×SSC/0.1% NP-40 for 2 minutes. The slides were stained 
with 4′-6,-diamidino-2-phenylindole (Vector Laboratories, 
Burlingame, CA) and coverslipped.
Visualization of the FISH signals was accomplished by 
use of a fluorescence microscope, and images were captured 
using a FISH imaging system. Two technologists (D.L.K. 
and S.M.K.) independently scored 100 interphase tumor cell 
nuclei (50 each), per case.
Statistical Analysis
Age was compared between presence and absence of 
MYB rearrangement using a two-sample t-test. Other charac-
teristics (patient sex, histologic pattern, extent of resection, 
and adjuvant therapy) were compared with Fisher’s exact tests. 
Overall survival and progression-free (no metastasis and/or 
recurrence) survival were compared between the groups with 
log-rank tests and were summarized with 5-year estimates 
using the Kaplan–Meier method. Analyses were performed 
using SAS version 9 (Cary, NC) or R.15
RESULTS
The histologic pattern and clinical ﬁndings of the 40 
PACC cases are summarized in Table 1. Immunohistochemistry 
was performed in 30 cases; the remainder of the cases had 
insufﬁcient tissue for study remaining in FFPE blocks. p63 
was expressed in the myoepithelial cells, and CD117 was 
expressed in the ductal-type cells in all cases tested (Fig. 1).
Tissue blocks for FISH studies were available in 35 
cases. Six (of 35) cases failed to hybridize. In the remaining 
29 cases, disruption of the MYB gene region was observed in 
12 (41.4%; Fig 1A–E), whereas 17 (58.6%) showed no evi-
dence of rearrangement (Fig. 1F–J). In 10 (of 12) MYB rear-
ranged tumors, more than 75% of the tumor nuclei showed a 
typical pattern for MYB rearrangement; one orange, one green, 
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and one fusion signal. An atypical MYB rearrangement was 
observed in two cases; one case with predominantly cribriform 
pattern showed one orange and one fusion (12% tumor nuclei), 
two fusion (54%), or three fusion (18%) signals, indicating 
loss of 3′ region of the MYB gene (Fig. 1K–O). Another case 
with predominantly solid pattern showed 53% of tumor nuclei 
with one orange, two green, and one fusion signals (suggesting 
duplication of 3′ region of MYB), whereas 23% of tumor cell 
nuclei exhibited one orange, one green, and one fusion signal.
To conﬁrm the speciﬁcity of MYB rearrangement for 
PACC, FISH was also performed on 10 adenocarcinomas, 10 
squamous cell carcinomas, and 5 small-cell carcinomas of the 
lung. No rearrangement of the MYB gene region was observed 
in any of these tumors.
There was no difference in age between MYB rear-
ranged and non-rearranged cases. Six (of 12, 50%) patients 
with PACC that were MYB rearranged and six (of 17, 35%) 
non-rearranged PACC were younger than 50 years. A slight 
female predominance was observed in both groups; how-
ever, there was no signiﬁcant difference between the groups. 
There was no difference in the frequency of histologic pat-
tern (tubular, cribriform, and solid) between MYB rearranged 
and MYB-intact cases. In both groups, the cribriform pattern 
was the most common architectural pattern (Fig. 1A–E, K–N), 
whereas solid architecture was least common.
Most patients underwent complete resection, and only 
a minority received adjuvant treatment (Table 1). Follow-up 
was available in all patients with PACC and shown in Table 1. 
There was no signiﬁcant difference in overall survival and 
progression-free survival between MYB rearranged and non-
rearranged tumors (Table 1, Fig. 2).
DISCUSSION
We identiﬁed MYB rearrangement in 41% of 29 cases 
of PACC. The frequency of detected gene rearrangement var-
ies greatly between studies. Although the original study by 
Persson et al.8 showed the t(6;9) in each of 11 head and neck 
and breast ACC tested, a subsequent study by Mitani et al.9 
only revealed this translocation in 28% of 72 primary head 
and neck ACC. Our results are similar to the ﬁndings by Brill 
et al.,14 who identiﬁed a 44% frequency of MYB–NFIB fusion 
in ACC of multiple sites and a 50% frequency of the fusion 
in 10 tracheobronchial ACC. The reason for the variation in 
the frequency of detected MYB–NFIB fusion products is not 
TABLE 1. Clinical, Histologic and Cytogenetic Features of Pulmonary Adenoid Cystic Carcinomas
All cases
MYB (N = 29)
PaRearranged Not Rearranged
Number of patients 40 12 17
Age at time of procedure in years, median (range) 56.6 (21.6–73.4) 53.0 (29.7–72.6) 53.8 (21.6–70.8) 0.75
Sex, number (%) 1.0
  Male 16 (40.0) 5 (41.7) 7 (41.2)
  Female 24 (60.0) 7 (58.3) 10 (58.8)
Histologic pattern, predominant, number (%) 0.80
  Cribriform 31 (77.5) 9 (75.0) 14 (82.4)
  Solid 3 (7.5) 1 (8.3) 2 (11.8)
  Tubular 6 (15.0) 2 (16.7) 1 (5.9)
Resection, number (%) 0.59
  Resection status known 15 5 8
  Complete 8 (53) 3 (60) 4 (50)
  Incomplete 2 (13) 0 2 (25)
  Biopsy 5 (33) 2 (40) 2 (25)
Positive lymph node, number (%) 2 (22)b 1 (50)c 0d
Adjuvant therapy, number (%) 13 (32.5) 4 (33.3) 8 (47.1) 0.68
Follow-up, years, median (range) 4.7 (0–34.3) 6.0 (0–25.2) 4.6 (0–20.6)
Outcome, number
  Death 29 10 11 0.95
  5-yr survival, % (95% CI) 50.0 (21.7, 78.3) 52.6 (26.6, 78.5)
  Death due to disease 12 5 6
  Metastasis or recurrence 23e 7 8f 0.83
  5-yr disease-free survival, % (95% CI) 30.0 (1.6, 58.4) 52.5 (20.6, 84.5)
ap value for comparison of MYB rearranged versus MYB not rearranged cases.
bInformation available in nine cases.
cInformation available in two cases.
dInformation available in six cases
eData unavailable in four cases.
fData unavailable in three cases.
CI, conﬁdence interval.
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entirely clear but likely multifactorial. For instance, detection 
techniques employed vary between studies. While we evalu-
ated for MYB rearrangements utilizing a break-apart FISH 
probe strategy, West et al.12 used a come-together and break-
apart FISH probe strategy with two probes flanking the MYB 
gene and one probe located at the 3′ end of the NFIB gene. 
Other studies8,9,14 analyzed MYB–NFIB fusion products by 
reverse-transcriptase polymerase chain reaction (RT-PCR). 
FISH may be able to identify a number of abnormalities in the 
region of the gene break points; using RT-PCR, on the other 
hand, the fusion variants detected are dependent on primer 
design and multiplexing.14 Furthermore, Brill et al.14 found 
the fusion oncogene in 86% of ACC when using fresh frozen 
tissue in contrast to 44% when using FFPE tissue. The authors 
attributed this large difference to degradation and chemical 
cross-linking of RNA caused by formalin ﬁxation and parafﬁn 
embedding. In addition, sample size might play a role. While 
the initial study by Persson et al.8 only included 11 cases of 
ACC, Mitani et al.9 studied 89 ACC. We solely used whole 
tissue sections, other studies utilized tissue microarrays.12 
However, given that in our study more than 75% of tumor cell 
nuclei of all MYB rearranged PACC showed a rearrangement 
pattern by FISH, tissue size might not be important, and MYB 
rearrangement studies might be useful even in small biopsies.
MYB rearrangement is considered highly speciﬁc for 
ACC and therefore might be helpful in the distinction of 
PACC from other carcinomas in the lung. This distinction 
is important because of differences in prognosis and treat-
ment. Even though metastases and/or recurrence are seen in 
approximately 40% of patients with PACC, studies show that 
FIGURE 2. Kaplan–Meier curves for overall (A) 
and progression-free (B) survival for patients with 
MYB rearranged and MYB not rearranged tumors.
FIGURE 1. Case 1: Low power view shows a cellular infiltrate in the submucosa of an airway (note respiratory mucosa, arrow 
A). At high magnification, small-to-medium-sized round to oval cells with eosinophilic or clear cytoplasm and inconspicu-
ous nucleoli surround mucoid matrix and grow in a cribriform pattern (B). A subset of neoplastic cells marks with p63 (C) and 
other neoplastic cells express CD117 (D). These findings are consistent with an adenoid cystic carcinoma. By fluorescence in 
situ hybridization (FISH) the MYB gene region is rearranged (one green, one red, and one fusion signal, E). Case 2: A cellular 
infiltrate is centered on a large airway (note cartilage left lower hand) with perineural invasion (arrow, F). This case is composed 
of cells that are cytologically similar to case 1 but are forming tubules (G). Myoepithelial cells mark with p63 (H), whereas ductal 
cells are positive for CD117 (I). The MYB gene region is preserved (two fusion signals, J). Case 3: Low magnification reveals a 
hypercellular nodule (K) with neoplastic cells growing in a cribriform pattern (L). Foci of necrosis are apparent. p63 marks myo-
epithelial cells (M), whereas the ductal cells stain weakly with CD117 (N). FISH reveals an irregular pattern with one orange and 
one fusion (arrowhead), or two fusion (arrow) signals (O). Magnification 12.5× (A, F, K), 400× (B–D, G–I, L–N), 1000×  
(oil immersion; E, J, O).
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the prognosis of PACC is superior to other carcinomas in the 
lung.1,2 PACC are reported to have a 5-year survival of 53% 
to 89%1,2 in contrast to 16.8% for lung and bronchus cancer 
(SEER database, updated 2011). In support of the high speci-
ﬁcity of t(6;9) for ACC, Mitani et al.9 studied 34 non-ACCs 
including myoepithelial carcinomas, acinic cell carcinomas, 
mucoepidermoid carcinomas, salivary duct carcinomas, 
polymorphous low-grade adenocarcinomas, and epithelial–
myoepithelial carcinomas; none of these tumors harbored the 
t(6;9). West et al.12 also evaluated a wide variety of non-ACC 
salivary gland tumors that included myoepithelioma, epithe-
lial–myoepithelial carcinoma, pleomorphic adenoma/cellular 
pleomorphic adenoma/carcinoma ex pleomorphic adenoma, 
oncocytic hyperplasia/oncocytoma/oncocytic carcinoma, 
basal cell adenoma/adenocarcinoma, salivary duct carcinoma, 
and adenosquamous carcinoma as well as tumors similar to 
those studied by Mitani et al.9 Each of these tumors was nega-
tive for MYB rearrangement or MYB–NFIB fusion. Of note, 
a single case of a polymorphous low-grade adenocarcinoma 
has been reported to harbor that translocation.16 We sought to 
conﬁrm the speciﬁcity of MYB rearrangement for ACC in the 
lung and to conﬁrm its utility in the distinction from potential 
morphologic mimickers in the lung. We tested 10 squamous 
cell carcinomas, 10 adenocarcinomas, and 5 small-cell carci-
nomas of the lung for MYB rearrangement. We did not identify 
MYB rearrangement in any of these non-ACC cases, further 
providing evidence for the speciﬁcity of this genetic signa-
ture and its clinical utility in making the diagnosis of PACC. 
However, although highly speciﬁc for ACC, the lack of this 
ﬁnding does not exclude a diagnosis of PACC, given that MYB 
rearrangement is only present in a subset of these tumors.
The association of MYB–NFIB fusion with clinical fea-
tures and prognostic signiﬁcance of ACC, if any, is not entirely 
clear. Mitani et al.9 found that MYB–NFIB fusion is associated 
with a patient’s age of more than 50 years. However, our results 
did not reveal an association between the presence of MYB 
rearrangement in PACC and age. Our results support previous 
study ﬁndings by West et al.,12 where an association between 
age and MYB rearrangement could not be elucidated. Similar 
to previous studies, we did not identify signiﬁcant differences 
in gender either.9,12 Furthermore, our study did not reveal a cor-
relation of MYB rearrangement with prognosis. Overall sur-
vival and progression-free survival did not statistically differ 
between patients with PACC that were MYB rearranged and 
those that were not. Our ﬁndings are similar to the study by 
Mitani et al.9 and D’Alfonso et al.11 that also showed no cor-
relation of t(6;9) and prognosis in ACC, including ACC of the 
breast. West et al.12 found a trend of ACC with MYB rearrange-
ment toward high relapse rate; however, that ﬁnding was not sta-
tistically signiﬁcant. Our results also conﬁrm previous studies, 
including a study of ACC in the breast, in which the presence 
of the MYB–NFIB fusion transcript does not correlate with out-
come.11 We also failed to identify an association between MYB 
rearrangement and histopathologic growth pattern. Although 
the lack of any association between MYB rearrangement and 
clinical or histopathologic ﬁndings might be in part because 
of the study size, the lack of a trend together with the results 
of other studies suggests that MYB rearrangement in PACC is 
unlikely to be associated with clinical ﬁndings, histopathologic 
features, or prognosis. Although our study sample size is rela-
tively low in comparison with studies of other primary lung 
carcinomas, it is quite large for PACC given its overall rarity. 
In fact, these cases were collected over a time period covering 
almost 40 years at a large institution. Therefore, a multicenter 
study is likely required to study a larger population of PACC.
The classic (6;9) translocation might not only serve 
diagnostic purposes, but potentially be of therapeutic interest 
as well given its relatively high prevalence in PACC. Although 
targeting MYB’s transcriptional function itself is challenging,17 
targeting molecules that are effected downstream of t(6;9) 
seems more promising. For instance, studies by Moskaluk 
et al.18 showed that low-passage primary ACC xenografts 
express spontaneously activated ﬁbroblast growth factor recep-
tor (FGFR)-1 receptors. This growth factor has been found to be 
upregulated in ACC cells with MYB overexpression and there-
fore is a candidate downstream effector of this oncoprotein.8,19 
In fact, clinical trials targeting ﬁbroblast growth factor or FGFR 
in ACC are currently underway.17 Other potentially targetable 
downstream effectors of MYB include cell proliferation pro-
teins (MYC, CD53, FGF2, VEGFA, KIT), cell cycle proteins 
(CCNB1, CDC2, MAD1L1), apoptosis-related markers (API5, 
BCL2, BIRC3, HSPA8, SET), and cellular adhesion molecules 
(CD34), some of which are already targeted in clinical trials.17,20
One of our MYB rearranged cases revealed loss of the 
3′ MYB region. This case was predominantly of cribriform 
architectural pattern. Previously, D’Alfonso et al.11 showed the 
monoallelic loss of the 5′ MYB region in a case of ACC with 
solid growth pattern and basaloid features of the breast. This 
tumor was reportedly negative for gene fusion or rearrange-
ment by RT-PCR and FISH. As mentioned earlier, West et al.12 
used a FISH come-together and break-apart assay using two 
probes flanking the MYB gene and one probe at the 3′ end of 
the NFIB gene. In this study, six (of 37) ACC had an abnormal 
FISH pattern including MYB 3′, MYB 5′, and NFIB all come-
together and an extra 5′ MYB without association with NFIB. 
These ﬁndings might indicate complex MYB rearrangements.
In conclusion, MYB rearrangement is helpful in the 
diagnosis of PACC given its speciﬁcity for ACC, although 
a negative result does not rule out the possibility of PACC. 
MYB rearrangement does not seem to be associated with his-
topathologic features, clinical ﬁndings, or prognosis of PACC. 
However, multicenter studies might be helpful to conﬁrm that 
ﬁnding in a larger patient population.
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